ArticlePulmonary circulation2025
Heart Rate Variability as a Marker of Disease Severity in Pulmonary Arterial Hypertension: A Prospective Cohort Study.
Article in Pulmonary circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nocturnal Hypoxaemia in PAH Patients Living at High Altitude Relocated to Low Altitude.Respiration; international review of thoracic diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a disease that can eventually progress to right ventricular failure. Heart rate variability (HRV), including standard deviation of R-to-R intervals (SDNN), has been associated with increased mortality across different populations. The purpose of this study was to examine the association between HRV and disease severity in PAH. This was a prospective cohort study of adult incident PAH patients who underwent cardiac magnetic resonance imaging (CMR) at baseline and following 6 months. Study subjects recorded HRV using wearable chest actigraphy devices for at least 1 h every 2 weeks. The primary end point was correlation between HRV and right ventricular ejection fraction (RVEF) on CMR. Multivariable mixed effects regression models were used. A total of 20 subjects completed the study, predominantly female and White race, with severe PAH at the time of enrollment that improved significantly following 6 months of treatment. Linear relationships were observed between HRV (SDNN) and measures of PAH severity on CMR, including RVEF (SDNN coefficient 0.18,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.